A novel nanobody-based immunocytokine of a mutant interleukin-2 as a potential cancer therapeutic.
Beig Parikhani A, Dehghan R, Talebkhan Y, Bayat E, Biglari A, Shokrgozar MA, Ahangari Cohan R, Mirabzadeh E, Ajdary S, Behdani M.
Beig Parikhani A, et al.
AMB Express. 2024 Feb 9;14(1):19. doi: 10.1186/s13568-023-01648-2.
AMB Express. 2024.
PMID: 38337114
Free PMC article.
In this study, a novel nanobody-based immunocytokine is developed by the fusion of a mutant (m) IL-2 with a decreased affinity toward CD25 to an anti-vascular endothelial growth factor receptor-2 (VEGFR2) specific nanobody, denoted as VGRmIL2-IC. ...
In this study, a novel nanobody-based immunocytokine is developed by the fusion of a mutant (m) IL-2 with a decreased affinity toward …